JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2013, Vol. 51 ›› Issue (11): 25-29.

• Articles • Previous Articles     Next Articles

Vascular endothelial growth factor (VEGF) promotes lung carcinoma metastasis via VEGFR1 in mouse model

XU Xiao-ya, BI Yu-li, JIANG Man, XU Ji-ying, ZHANG Peng-fei, HAN Ming-yong   

  1. Cancer Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China
  • Received:2013-06-23 Online:2013-11-10 Published:2013-11-10

Abstract:

Objective  To investigate the mechanism by which vascular endothelial growth factor (VEGF) promotes lung metastasis. Methods  VEGF levels of nine human lung carcinoma cell lines were examined with ELISA and the proliferation was tested by MTT. Two cell lines with distinctive VEGF expression and similar proliferation were subcutaneously injected to the back of SCID mice or intravenously injected by the tail vein to build the metastasis model. The volume of tumors on back of mice were measured every 3 days till sacrificed. Pulmonary metastasis and vascular density were verified by HE staining and CD31 immunofluorescence. Neutralizing antibodies specific for mouse VEGFR1 (MF1) and VEGFR2 (DC101) were administrated to verify which receptor was involved in VEGF induced  pulmonary metastases. Results  ELISA showed that VEGF levels of nine human lung carcinoma cell lines were in a range of 13.39-182.7ng/mL. A549 cell with high VEGF expression (182.7ng/mL) and SPCA1 with low VEGF expression (13.39ng/mL) were chosen to build mouse model. The proliferation of A549 and SPCA1 had no significant difference. A549 cell formed much larger tumor on the back of SCID mice than SPCA1. Angiogenesis in A549 formed tumor was significantly increased than SPCA1 formed tumor (P<0.01). In lung metastasis model, number of metastatic lesions in lung tissues found in A549 mice was 2.3 folds compared with SPCA1. After treatment with anti-mouse VEGFR1 monoclonal antibody, the total number of metastatic tumors induced by A549 decreased from 54 to 13, while anti-VEGFR2 treatment had no significant difference in metastasis numbers(P>0.05). Conclusion  VEGF secreted by lung cancer cells could promote tumor growth and tumor angiogenesis. VEGF promotes pulmonary metastasis by VEGFR1 pathways. The blockage of VEGFR1 induced metastasis may provide a novel approach for prevention and treatment of tumor metastasis.

Key words: Vascular endothelial growth factor; Metastasis; Vascular endothelial growth factor receptor; Lung carcinoma; Animal model

CLC Number: 

  • R734.2
[1] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(11): 108-110.
[2] TIAN Tian-tian1, LI Ji-sheng1, WANG Ya-wei1, MA Dao-xin2, WANG Xiu-wen1. Genistein exerts antitumor effects in small cell lung cancer H446 cells via suppressing the activity of FoxM1 pathway [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(06): 44-48.
[3] LIU Bing1, YU Zhuang1, HOU Xian-peng1, YAO Ru-yong2. Different expressions of EGFR and HER-3 genes in human lung adenocarcinoma cells and pemetrexed-resistant cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(5): 20-23.
[4] ALIMUJIANG·Stiwaerdi, ZHANG Tao, PATIGULI·Aerxiding, LIU Li. Clinical analysis of recombinant human endostatin combined with gemcitabine and  cisplatin therapy in advanced non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(3): 95-98.
[5] DONG Xue-li, MU Xiao-yan, LIU Qing-liang, SUN Jie. Effects of erlotinib combined with celecoxib on growth and angiogenesis of human lung cancer xenograft model [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2013, 51(2): 49-52.
[6] . [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(10): 130-131.
[7] LIU Qing-liang1, MU Xiao-yan1, WANG-Jing2, CHI Xiang-yu2, ZHANG Min3, MA Wei-xia3. Inhibitory effects of RNA interference and Erlotinib by blocking epidermal
growth factor receptor pathway on the proliferation of A549 cells
[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 11-.
[8] FAN Heng-jian, ZHANG Yu-ke, XIAO Wei, ZHANG Yi, LI Hai-jun, WANG De-xiang. Changes of Treg and Th17 cells in the peripheral bloods of patients with
lung adenocarcinoma and their prognostic significance
[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 73-78.
[9] WANG Ji-xia, LI Gui-xin, HUANG Yan, WANG Li-juan. Expressions and clinical significances of E1AF,MMP-7 and uPA in nonsmall cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 109-.
[10] XU Tong-zhen, SUN Xue-fei, REN Dong-mei, YANG Guo-tao. Antiproliferation activity of luteolin and its role in combined chemotherapy on lung cancer A549 cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(7): 50-54.
[11] LIU Hai-rong1, YU Jin-ming2, LI Yan1, LIANG Jing1, LIU Xiao-lin1. Study of the relationship between ER, PR, C-erB-2 and
bone metastasis of  lung adenocacinoma
[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(4): 91-.
[12] MA Yu-hua1,2, ZHENG Yan3, JIA Yan-fei3, WANG Yun-shan3. GFR and DEC1 protein co-expression promotes lymph node
metastasis in lung adenocarcinoma
[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(3): 24-28.
[13] SUN Xue-fei, PEI Yan-tao,YIN Qiu-wei, YANG Guo-tao, WANG De-jiang. Inhibitory effect of Radix Actinidiae extractive on transplantation
tumor of the lung cancer cell line A549 in nude mice
[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(2): 38-42.
[14] LI Peng, LIU Qi, HAN Ming-yong. PET/CT,CEA and CYFRA21-1 predicting the therapeutic effect of targeted drug on non-small cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(1): 129-132.
[15] JIANG Xiao-dong1,2, DAI Peng2, WU Jin2, SONG Da-an2, YU Jin-ming3. Weekly recombinant human endostatin as a hypoxic tumor cell radio sensitizer combined with radiotherapy for non-small-cell lung cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 108-.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!